Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning

Acta Haematologica

Volumn 112, Issue 1-2, 2004, Pages 93-104

  Shimoni, Avichai ^a   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Lymphocyte infusion, donor; Minimal residual disease; Nonmyeloablative conditioning; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; ERADICATION THERAPY; FOLLICULAR LYMPHOMA; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; REVIEW;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; TRANSPLANTATION CONDITIONING;

EID: 2642587954     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077564     Document Type: Review

References (83)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Nieman PE, Lender KG, Glucksberg H, Buckner CD: Bone marrow transplantation. N Engl J Med 1975;292:832-843.
2. Armitage JO: Bone marrow transplantation. N Engl J Med 1994;330:827-838.
3. Champlin R, Khouri, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P: Harnessing graft-versus-malignancy: Nonmyeloablative preparative regimens for allogeneic haematopoietic transplantation. An evolving strategy for adoptive immunotherapy. Br J Haematol 2000;11:18-29.
4. Slavin S, Nagler A, Naparstek E, Kapelushnik J, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
5. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
6. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF: Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
7. Shimoni A, Nagler A: Non-myeloablative stem cell transplantation (NST): Chimerism testing as guidance for immune-therapeutic manipulations. Leukemia 2001;15:1967-1975.
8. Childs R, Clave E, Contentin N, Jayasekara D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241.
9. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R: Melphalan and purine analogcontaining preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637.
10. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, Garcia-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation: Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121-3127.
11. Prigozhina T, Gurevitch O, Slavin S: Non-myeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol 1999;27:1503-1510.
12. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-vs-host disease. Blood 1992;80:2964-2968.
13. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan LY, Ferrara JLM: Total body irradiation and acute graft-vs-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997;90:3204-3213.
14. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412-415.
15. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar C, Hale G, Waldmann H, Steinberg SM, Slavin S: T-cell depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995;89:506-515.
16. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R: Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-762.
17. Toren A, Rechavi G, Nagler A: Minimal residual disease post bone-marrow transplantation for hemato-oncological diseases. Stem Cells 1996;14:300-311.
18. Cohen N, Novikov I, Hardan I, Esa A, Brok-Simoni F, Amariglio N, Rechavi G, Ben-Bassat I, Trakhtenbrot L: Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 2000;123:102-108.
19. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia 2003;17:1013-1034.
20. Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P: Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998;92:574-588.
21. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Oji Y, Oka Y, Sugiyama H: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-1704.
22. Gruhn B, Hafer R, Voigt A, Pfaffendorf N, Wittig S, Fuchs D, Zintl F: Clinical significance of minimal residual disease after hematopoietic stem cell transplantation. Blood 2002;100:176a.
23. Munoz L, Aventin A, Villamor N, Junca J, Acebedo G, Domingo A, Rozman M, Torres JP, Tormo M, Nomdedeu JF: Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica 2003;88:637-645.
24. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T, Hiddemann W: Analysis of FLT3 length mutations in 1,003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
25. Nagler A, Condiotti R, Rabinowitz R, Schlesinger M, Nguyen M, Terstappen LW: Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC). Med Oncol 1999;16:177-187.
26. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M, Caballero D, Garcia-Marcos MA, Ramos F, Fernandez-Calvo J, Calmuntia MJ, Diaz-Mediavilla J, Orfao A: Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465-2470.
27. Thiede C, Bornhäuser M, Oelschlagel U, Brendel C, Leo R, Daxberger H, Mohr B, Florek M, Kroschinsky F, Geissler G, Naumann R, Ritter M, Prange-Krex G, Lion T, Neubauer A, Ehninger G: Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001;15:293-302.
28. Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D, Peters C, Matthes-Martin S, Lawitschka A, Gadner H: Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001;15:307-310.
29. Nagler A, Slavin S, Yarkoni S, Fejgin M, Amiel A: Detection of minimal residual disease after sex-mismatch bone marrow transplantation in chronic myelogenous leukemia by fluorescence in situ hybridization. Cancer Genet Cytogenet 1994;73:130-133.
30. Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I, Yeshurun M, Daniely M, Zilberstein Y, Amariglio N, Brok-Simoni F, Rechavi G, Trakhtenbrot L: Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis. Leukemia 2002;16:1413-1418.
31. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR, Thomas ED: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. Blood 1995;85:2632-2638.
32. Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L, Edmands S, Flowers ME, Kerkof K, Nelson R, Appelbaum FR: The significance of bcr-abl molecular detection in chronic myeloid leukemia patients 'late', 18 months or more after transplantation. Blood 2001;98:1701-1707.
33. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NC, Goldman JM: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97:1560-1565.
34. Lin F, van Rhee F, Goldman JM, Cross NC: Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996;87:4473-4478.
35. Giralt SA, Goldman J, Anasetti C, Cervantes F, Champlin R, Cross N, Hochhaus A, Klein JP, Papadopoulos E, Sobocinski K, Weisdorf D, Horwitz M, on behalf of the Chronic Leukemia Working Committee of the IBMTR: Recommendations for assessment and definitions of response and relapse in CMK: A report from the Chronic Leukemia Working Committee of the IBMTR; in Carella AM, Daley DQ, Eaves CJ, Goldman JM, Hehlmann R (eds): Chronic Myeloid Leukemia: Biology and Treatment. London, Dunitz, 2001, pp 357-368.
36. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S: Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441-445.
37. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringden O: Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003;101:469-472.
38. Childs R, Epperson D, Bahceci E, Clave E, Barrett J: Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia effect. Br J Haematol 1999;107:396-400.
39. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, Jones CG, Rowbottom AW, Hunt LP, Green AF, Clarke E, Lankester AW, Cornish JM, Pamphilon DH, Steward CG, Oakhill A: Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998;92:4072-4079.
40. Knechtli CJ, Goulden NJ, Hancock JP, Harris EL, Garland RJ, Jones CG, Grandage VL, Rowbottom AW, Green AF, Clarke E, Lankester AW, Potter MN, Cornish JM, Pamphilon DH, Steward CG, Oakhill A: Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998;102:860-871.
41. Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, Prentice HG, Goldstone A, Hoffbrand AV, Foroni L: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002;20:1094-1104.
42. Miglino M, Berisso G, Grasso R, Canepa L, Clavio M, Pierri I, Pietrasanta D, Gatto S, Varaldo R, Ballerini F, Verdiani S, Casarino L, DeStefano F, Sessarego M, Dominietto A, Raiola AM, Bregante S, di Grazia C, Gobbi M, Bacigalupo A: Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): Predictive role of minimal residual disease monitoring on relapse. Bone Marrow Transplant 2002;30:579-585.
43. Radich J, Ladne P, Gooley T: Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT. Biol Blood Marrow Transplant 1995;1:24-31.
44. Uzunel M, Jaksch M, Mattsson J, Ringden O: Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Br J Haematol 2003;122:788-794.
45. Sanchez J, Serrano J, Gomez P, Martinez F, Martin C, Madero L, Herrera C, Garcia JM, Casano J, Torres A: Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002;116:686-694.
46. Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY, Park YH, Shin HJ, Park CY, Min WS, Kim HK, Kim CC: Risk factors for adults with Philadelphia- chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: The potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003;120:145-153.
47. Yin JA, Grimwade D: Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002;360:160-162.
48. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, Block AM, Knuutila S, Herzig GP, Bloomfield CD: Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996;88:2183-2191.
49. Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA, Morgan G, Lucas GS, Liu Yin JA: Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000;95:815-819.
50. Laczika K, Mitterbauer G, Mitterbauer M, Knobl P, Schwarzinger I, Greinix HT, Rabitsch W, Fonatsch C, Mannhalter C, Lechner K, Jaeger U: Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RTPCR: Implications for a monitoring schedule and for treatment decisions. Leuk Lymphoma 2001;42:923-931.
51. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, Amabile M, Terragna C, Ruggeri D, Piccaluga PP, Isidori A, Malagola M, Baccarani M, Tura S, Martinelli G: Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002;99:443-449.
52. Shimoni A, Nagler A, Bielorai B, Reichart M, Rothman R, Toren A, Rechavi G, Amariglio N, Trakhtenbrot L: Detection of host blasts but not mature hematopoietic cells among minute host populations remaining after allogeneic transplantation, using combined morphological and cytogenetic analysis, predicts imminent relapse. Blood 2002;100:631a.
53. Perez-Simon JA, Caballero D, Diez-Campelo M, Lopez-Perez R, Mateos G, Canizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF: Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002;16:1423-1431.
54. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles F, San Miguel J, Sierra J: Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study. Haematologica 2003;88:555-560.
55. Esteve J, Villamor N, Colomer D, Montserrat E: Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood 2002;99:1873-1874.
56. Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Höffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reducedintensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 2003;21:2747-2753.
57. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT: Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003;17:841-848.
58. Ritgen M, Dreger P, Humpe A, Stilgenbauer S, Döhner H, Kneba M: Quantitative PCR demonstrates effective graft-versus-leukemia activity after allogeneic stem cell transplantation using reduced intensity conditioning in patients with chronic lymphocytic leukemia (CLL). Blood 2002;100,854a.
59. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001;98:3595-3599.
60. Mitterbauer M, Neumeister P, Kalhs P, Brugger S, Fischer G, Dieckmann K, Hoecker P, Hinterberger W, Linkesch W, Simonitsch I, Jaeger U, Lechner K, Mannhalter C, Mitterbauer G, Greinix HT: Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 2001;15:635-641.
61. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S: Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: An intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001;27:821-828.
62. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT): Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927-1929.
63. Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P, Lemoli RM, Benni M, Pagliani G, Bandini G, Tura S: Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000;96:355-357.
64. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
65. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
66. Dazzi F, Szydlo RM, Goldman JM: Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand. Exp Hematol 1999;27:1477-1486.
67. Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K: Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003;9:257-265.
68. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;83:3377-3383.
69. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, Olavarria E, van Rhee F, Kanfer E, Apperley JF, Goldman JM: Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000;95:67-71.
70. Dazzi F: Monitoring of minimal residual disease after allografting: A requirement to guide DLI treatment? Ann Hematol 2002;81(suppl 2):S29-S30.
71. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, Collins RH Jr: Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002;20:405-412.
72. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P, Niethammer D, Beck JF: Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children. Leukemia 1999;13:2079-2086.
73. Shimoni A, Trakhtenbrot L, Bielorai B, Reichart M, Rothman R, Toren A, Rechavi G, Nagler A: Application of immune-therapeutic interventions after allogeneic transplantation based on MRD detection with combined morphological and cytogenetic analysis. Biol Bone Marrow Transplant 2003;9:68a.
74. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD: The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002;100:3108-3114.
75. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N, Sachs DH, Sykes M, Spitzer TR: Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003;9:320-329.
76. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M: Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 2002;100:1903-1909.
77. Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G, Dörken B, Arnold R: Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003;31:339-345.
78. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M: Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002;99:75-82.
79. de Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I, Tavares R, Lerner D, Byington R, Bouzas L, da Matta J, Andrade C, Carvalho L, Pires V, Barone B, Maciel C, Tabak D: Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: High remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001;27:73-78.
80. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G: Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20:1295-1303.
81. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T: Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:1707-1712.
82. Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A: Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003;17:290-297.
83. Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, Nagler A: Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003;122:457-464.